2023-03-16 16:33:07 ET
- Panbela Therapeutics press release ( NASDAQ: PBLA ): Q4 GAAP EPS of -$5.68 misses by $2.08 .
- General and administrative expenses were $1.7 million in the fourth quarter of 2022, compared to $1.3 million in the fourth quarter of 2021.
- Research and development expenses were $3.5 million in the fourth quarter of 2022, compared to $2.0 million in the fourth quarter of 2021.
- Total cash was $1.3 million as of December 31, 2022. Total current assets were $1.8 million and current liabilities were $7.8 million as of the same
For further details see:
Panbela Therapeutics GAAP EPS of -$5.68 misses by $2.08